Search Results - "PAVLOVA, Sarka"

Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene by Doffe, Flora, Carbonnier, Vincent, Tissier, Manon, Leroy, Bernard, Martins, Isabelle, Mattsson, Johanna S. M., Micke, Patrick, Pavlova, Sarka, Pospisilova, Sarka, Smardova, Jana, Joerger, Andreas C., Wiman, Klas G., Kroemer, Guido, Soussi, Thierry

“…Infrequent and rare genetic variants in the human population vastly outnumber common ones. Although they may contribute significantly to the genetic basis of a…”
Get full text

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia by Plešingerová, Hana, Janovská, Pavlína, Mishra, Archana, Smyčková, Lucie, Poppová, Lucie, Libra, Antonín, Plevová, Karla, Ovesná, Petra, Radová, Lenka, Doubek, Michael, Pavlová, Šárka, Pospíšilová, Šárka, Bryja, Vítězslav

“…Chronic lymphocytic leukemia is a disease with up-regulated expression of the transmembrane tyrosine-protein kinase ROR1, a member of the Wnt/planar cell…”
Get full text

Unveiling the dynamics and molecular landscape of a rare chronic lymphocytic leukemia subpopulation driving refractoriness: insights from single‐cell RNA sequencing by Kurucova, Terezia, Reblova, Kamila, Janovska, Pavlina, Porc, Jakub Pawel, Navrkalova, Veronika, Pavlova, Sarka, Malcikova, Jitka, Plevova, Karla, Tichy, Boris, Doubek, Michael, Bryja, Vitezslav, Kotaskova, Jana, Pospisilova, Sarka

“…Early identification of resistant cancer cells is currently a major challenge, as their expansion leads to refractoriness. To capture the dynamics of these…”
Get full text

Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene by Poppova, Lucie, Pavlova, Sarka, Gonzalez, Beatriz, Kotaskova, Jana, Plevova, Karla, Dumbovic, Gabrijela, Janovska, Pavlina, Bystry, Vojtech, Panovska, Anna, Bezdekova, Lucie, Maslejova, Stanislava, Brychtova, Yvona, Doubek, Michael, Krzyzankova, Marcela, Borsky, Marek, Mayer, Jiri, Bryja, Vitezslav, Alonso, Sergio, Pospisilova, Sarka

“…Genome methylation profiles define naïve-like (n-CLL), memory-like (m-CLL), and intermediate (i-CLL) subsets of chronic lymphocytic leukaemia (CLL). The…”
Get full text

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes by Olbertova, Helena, Plevova, Karla, Pavlova, Sarka, Malcikova, Jitka, Kotaskova, Jana, Stranska, Kamila, Spunarova, Michaela, Trbusek, Martin, Navrkalova, Veronika, Dvorackova, Barbara, Tom, Nikola, Pal, Karol, Jarosova, Marie, Brychtova, Yvona, Panovska, Anna, Doubek, Michael, Pospisilova, Sarka

“…Telomeres are protective structures at chromosome ends which shorten gradually with increasing age. In chronic lymphocytic leukemia (CLL), short telomeres have…”
Get full text

Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage by Mancikova, Veronika, Pesova, Michaela, Pavlova, Sarka, Helma, Robert, Zavacka, Kristyna, Hejret, Vaclav, Taus, Petr, Hynst, Jakub, Plevova, Karla, Malcikova, Jitka, Pospisilova, Sarka

“…TP53 gene abnormalities represent the most important biomarker in chronic lymphocytic leukemia (CLL). Altered protein modifications could also influence p53…”
Get full text

The Absence of Retroelement Activity Is Characteristic for Childhood Acute Leukemias and Adult Acute Lymphoblastic Leukemia by Urazbakhtin, Shamil, Smirnova, Anastasia, Volakhava, Anastasiya, Zerkalenkova, Elena, Salyutina, Maria, Doubek, Michael, Jelinkova, Hana, Khudainazarova, Nelly, Volchkov, Egor, Belyaeva, Laima, Komech, Ekaterina, Pavlova, Sarka, Lebedev, Yuri, Plevova, Karla, Olshanskaya, Yulia, Komkov, Alexander, Mamedov, Ilgar

“…Retroelements (RE) have been proposed as important players in cancerogenesis. Different cancer types are characterized by a different level of tumor-specific…”
Get full text

ROR1‐based immunomagnetic protocol allows efficient separation of CLL and healthy B cells by Kotašková, Jana, Pavlová, Šárka, Greif, Igor, Stehlíková, Olga, Plevová, Karla, Janovská, Pavlína, Brychtová, Yvona, Doubek, Michael, Pospíšilová, Šárka, Bryja, Vítězslav

Get full text

ToTem: a tool for variant calling pipeline optimization by Tom, Nikola, Tom, Ondrej, Malcikova, Jitka, Pavlova, Sarka, Kubesova, Blanka, Rausch, Tobias, Kolarik, Miroslav, Benes, Vladimir, Bystry, Vojtech, Pospisilova, Sarka

“…High-throughput bioinformatics analyses of next generation sequencing (NGS) data often require challenging pipeline optimization. The key problem is choosing…”
Get full text

Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells by Dave, Zankruti, Vondálová Blanářová, Olga, Čada, Štěpán, Janovská, Pavlína, Zezula, Nikodém, Běhal, Martin, Hanáková, Kateřina, Ganji, Sri Ranjani, Krejci, Pavel, Gömöryová, Kristína, Peschelová, Helena, Šmída, Michal, Zdráhal, Zbyněk, Pavlová, Šárka, Kotašková, Jana, Pospíšilová, Šárka, Bryja, Vítězslav

“…Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are malignancies characterized by the dependence on B-cell receptor (BCR) signaling and by…”
Get full text

Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones by Plevova, Karla, Francova, Hana Skuhrova, Burckova, Katerina, Brychtova, Yvona, Doubek, Michael, Pavlova, Sarka, Malcikova, Jitka, Mayer, Jiri, Tichy, Boris, Pospisilova, Sarka

“…In chronic lymphocytic leukemia, usually a monoclonal disease, multiple productive immunoglobulin heavy chain gene rearrangements are identified sporadically…”
Get full text

Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities by Stamatopoulos, Kostas, Pavlova, Sarka, Al‐Sawaf, Othman, Chatzikonstantinou, Thomas, Karamanidou, Christina, Gaidano, Gianluca, Cymbalista, Florence, Kater, Arnon P., Rawstron, Andy, Scarfò, Lydia, Ghia, Paolo, Rosenquist, Richard

“…Patients with chronic lymphocytic leukemia (CLL) exhibit diverse clinical outcomes. An expanding array of genetic tests is now employed to facilitate the…”
Get full text

ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin by Navrkalova, Veronika, Sebejova, Ludmila, Zemanova, Jana, Kminkova, Jana, Kubesova, Blanka, Malcikova, Jitka, Mraz, Marek, Smardova, Jana, Pavlova, Sarka, Doubek, Michael, Brychtova, Yvona, Potesil, David, Nemethova, Veronika, Mayer, Jiri, Pospisilova, Sarka, Trbusek, Martin

“…ATM abnormalities are frequent in chronic lymphocytic leukemia and represent an important prognostic factor. Sole 11q deletion does not result in ATM…”
Get full text

Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naïve CLL patients by Navrkalova, Veronika, Plevova, Karla, Radova, Lenka, Porc, Jakub, Pal, Karol, Malcikova, Jitka, Pavlova, Sarka, Doubek, Michael, Panovska, Anna, Kotaskova, Jana, Pospisilova, Sarka

“…Large-scale next-generation sequencing (NGS) studies revealed extensive genetic heterogeneity, driving a highly variable clinical course of chronic lymphocytic…”
Get full text

TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia by Malcikova, Jitka, Pavlova, Sarka, Kozubik, Katerina Stano, Pospisilova, Sarka

“…ABSTRACT In leukemia, TP53 mutations are not frequent but clearly associate with impaired survival and therapy response. Here, we describe the biological and…”
Get full text

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options by Malcikova, Jitka, Pavlova, Sarka, Kunt Vonkova, Barbara, Radova, Lenka, Plevova, Karla, Kotaskova, Jana, Pal, Karol, Dvorackova, Barbara, Zenatova, Marcela, Hynst, Jakub, Ondrouskova, Eva, Panovska, Anna, Brychtova, Yvona, Zavacka, Kristyna, Tichy, Boris, Tom, Nikola, Mayer, Jiri, Doubek, Michael, Pospisilova, Sarka

“…Patients with chronic lymphocytic leukemia (CLL) bearing TP53 mutations experience chemorefractory disease and are therefore candidates for targeted therapy…”
Get full text

PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells by Jaskova, Zuzana, Pavlova, Sarka, Malcikova, Jitka, Brychtova, Yvona, Trbusek, Martin

“…•PRIMA-1MET is effective in both TP53-mutated and TP53-wt CLL cells.•PRIMA-1MET induces apoptosis of TP53-mutated CLL cells irrespective of baseline p53…”
Get full text

Detection and Functional Analysis of TP53 Mutations in CLL by Pavlova, Sarka, Smardova, Jana, Tom, Nikola, Trbusek, Martin

“…Chronic lymphocytic leukemia (CLL) represents a prototype disease in which TP53 gene defects lead to inferior prognosis. Here, we present two distinct…”
Get more information

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia by Janovska, Pavlina, Verner, Jan, Kohoutek, Jiri, Bryjova, Lenka, Gregorova, Michaela, Dzimkova, Marta, Skabrahova, Hana, Radaszkiewicz, Tomasz, Ovesna, Petra, Vondalova Blanarova, Olga, Nemcova, Tereza, Hoferova, Zuzana, Vasickova, Katerina, Smyckova, Lucie, Egle, Alexander, Pavlova, Sarka, Poppova, Lucie, Plevova, Karla, Pospisilova, Sarka, Bryja, Vitezslav

“…Casein kinase 1δ/ε (CK1δ/ε) is a key component of noncanonical Wnt signaling pathways, which were shown previously to drive pathogenesis of chronic lymphocytic…”
Get full text

Second Line Treatment with Bruton Tyrosine Kinase Inhibitor (BTKi) or Bcl-2 Inhibitor (Bcl-2i) in Patients with Chronic Lymphocytic Leukemia (CLL): Primary Analysis of the Czech Study Group for CLL (CSCLL) by Mihalyova, Jana, Panovska, Anna, Simkovic, Martin, Turcsanyi, Peter, Spacek, Martin, Brejcha, Martin, Lysak, Daniel, Mocikova, Heidi, Pavlova, Sarka, Chrapava, Marika, Zuchnicka, Jana, Brychtova, Yvona, Vodarek, Pavel, Urbanova, Renata, Likarova, Tereza, Malcikova, Jitka, Jurkova, Tereza, Lancova, Klara, Bezdekova, Lucie, Papajik, Tomas, Baranova, Jana, Arpas, Tomas, Pospisilova, Sarka, Smolej, Lukas, Doubek, Michael

“…Introduction: Venetoclax in combination with rituximab (VenR) along with either ibrutinib or acalabrutinib monotherapy represent the most common regimens…”
Get full text